Zai Lab (ZLAB) Rebounds On A Fair Value Debate, Is It Still Below Fair Value?

Zai Lab (ZLAB) has drawn attention after its recent share move, with the price closing at US$24.58. The biopharmaceutical group now reflects a market value of about US$2.7b.

The recent 1 day share price return of 1.82% contrasts with a 7 day share price return that fell 6.29%, while the 90 day share price return of 38.64% points to building momentum. Over the past year, total shareholder return declined 22.99%, highlighting how Zai Lab’s recent rebound still sits against a longer stretch of weak overall investor outcomes.

Scan how Zai Lab compares to other potential rebound candidates by reviewing a curated list of 35 high quality undervalued stocks that combine resilient balance sheets with meaningful cash generation potential.

Zai Lab’s bounce over the past quarter sets up a familiar fork in the road for investors. Does the current valuation already reflect that reset, or is patience still rewarded from here?

Most Popular Narrative: 26% Undervalued

Against Zai Lab’s last close at $24.58, the most followed narrative sets fair value at $33.30. This points to a sizeable valuation gap that hinges on how its pipeline and China footprint translate into future cash flows under a 7.87% discount rate.

The maturing population in China and globally is expected to fuel sustained demand for innovative chronic and complex disease treatments (e.g., in oncology and autoimmunity), creating a large and expanding patient pool that will underpin durable revenue growth for Zai Lab's existing and upcoming therapies.

Improved clinical and regulatory execution (e.g., multiple ongoing pivotal trials, FDA Fast Track/Orphan Drug designations, and anticipated accelerated approvals both in China and globally) positions Zai Lab to bring therapies to market faster, reducing time-to-revenue and supporting a long-term positive earnings trajectory.

See why 12 investors see Zai Lab as 26% undervalued.

Result: Fair Value of $33.30 (UNDERVALUED)

Still, that story can break if heavy reliance on licensed assets keeps margins under pressure or if China pricing and reimbursement decisions slow uptake on new therapies.

Find out about the key risks to this Zai Lab narrative.

Next Steps

Mixed signals like these around Zai Lab only matter if you act on them. Move quickly to review the full picture in the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Zai Lab?

If Zai Lab has sharpened your appetite for opportunity, do not stop here. Broaden your watchlist with focused stock ideas built from clear, rules-based screeners.

• Target undervalued quality by reviewing a curated mix of durable businesses in the 35 high quality undervalued stocks that pair solid fundamentals with appealing price tags.
• Prioritise resilience and sleep-better-at-night balance sheets by scanning the list of solid balance sheet and fundamentals (23 results) to spot companies with room to handle shocks.
• Explore potential opportunities by combing through the 15 high quality undiscovered gems and see which lesser-known stocks already show strong underlying numbers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com